Ara-C, Idarubicine and Gentuzumab Advanced Acute Myeloid Leukemia Patients

Long-term survival of relapsed/refractory acute myeloid leukemia (AML) major problem, particularly in patients not eligible for transplantation. We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant. Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patient s, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant. Introduction. Patients with recurrent or refractory acute myeloid leukemia (AML) have a poor prognostic likelihood. Salvage regimens generally include high dose Ara-C, but whenever a second CR is attained, the median duration of a second relapse-free interval